Cover Image
市場調查報告書

特發性 (原發性) 高血壓:全球臨床實驗檢討

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

出版商 GlobalData 商品編碼 247625
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
特發性 (原發性) 高血壓:全球臨床實驗檢討 Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014
出版日期: 2014年09月21日 內容資訊: 英文 113 Pages
簡介

原因不明的高血壓便被稱為特發性高血壓,佔高血壓的95%。導致高血壓的致病因子因患者不同而會產生不同的障礙。特發性高血壓的症狀有頭痛、鼻血、呼吸急促、倦怠感、胸部疼痛等。診斷方面使用身體檢查、血壓檢測、尿液檢查、血液檢驗、心電圖等。治療方法依血壓不同各異,主要以藥物療法及改善生活習慣為主。企併症有動脈粥狀硬化性心血管疾病、心臟病發作、中風、心臟肥大、腎臟障礙等。

本報告提供特發性 (原發性) 高血壓的疼痛相關臨床研究最新趨勢分析,提供您疾病·治療方法概要,G7及E7各國的臨床實驗狀況,地區、PHASE、階段別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

簡介

  • 特發性 (原發性) 高血壓
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 前五名國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量: 特發性 (原發性) 高血壓 臨床實驗數量上心臟血管臨床實驗數量所佔的比例

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量: 特發性 (原發性) 高血壓 臨床實驗數量上心臟血管臨床實驗數量所佔的比例

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目臨床實驗數量別

未完成的臨床實驗

一定期間所採用的被實驗人數

贊助商的不同種類的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 特發性 (原發性) 高血壓 治療藥

有潛力的藥劑

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • Novartis AG
    • C. H. Boehringer Sohn AG & Co. KG
    • 武田藥品工業
    • 第一三共
    • Merck & Co., Inc.
    • Medionics International Inc
    • Bayer AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Les Laboratoires Servier SAS
  • 有代表性的研究機關醫院臨床實驗概要
    • Institut de Recherches Internationales Servier
    • Regional Hospital Holstebro
    • National Heart, Lung, and Blood Institute
    • University of Erlangen-Nurnberg
    • University of Pavia
    • St. George's University of London
    • Central South University
    • 愛媛大學大學院醫學系研究科
    • 菰野健康福利醫院
    • 岡山大學大學院醫生牙齒藥學綜合研究科

5大臨床實驗簡介

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" provides data on the Idiopathic (Essential) Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Idiopathic (Essential) Hypertension
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Idiopathic (Essential) Hypertension
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • C. H. Boehringer Sohn AG & Co. KG
      • Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Daiichi Sankyo Company, Limited
      • Clinical Trial Overview of Daiichi Sankyo Company, Limited
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Medionics International Inc
      • Clinical Trial Overview of Medionics International Inc
      • Bayer AG
      • Clinical Trial Overview of Bayer AG
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Les Laboratoires Servier SAS
      • Clinical Trial Overview of Les Laboratoires Servier SAS
    • Clinical Trial Overview of Top Institutes / Government
      • Institut de Recherches Internationales Servier
      • Clinical Trial Overview of Institut de Recherches Internationales Servier
      • Regional Hospital Holstebro
      • Clinical Trial Overview of Regional Hospital Holstebro
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • University of Erlangen-Nurnberg
      • Clinical Trial Overview of University of Erlangen-Nurnberg
      • University of Pavia
      • Clinical Trial Overview of University of Pavia
      • St. George's University of London
      • Clinical Trial Overview of St. George's University of London
      • Central South University
      • Clinical Trial Overview of Central South University
      • Ehime University Graduate School of Medicine
      • Clinical Trial Overview of Ehime University Graduate School of Medicine
      • Komono Kosei Hospital
      • Clinical Trial Overview of Komono Kosei Hospital
      • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      • Clinical Trial Overview of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Medionics International Inc, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Les Laboratoires Servier SAS, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut de Recherches Internationales Servier, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Regional Hospital Holstebro, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Erlangen-Nurnberg, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pavia, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by St. George's University of London, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Central South University, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Ehime University Graduate School of Medicine, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Komono Kosei Hospital, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2014*

List of Figures

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top